Prioritizing Data Security Through Digital Transformation In Biomanufacturing

By John Atkinson, Global Head of Information Security Office, FUJIFILM Diosynth Biotechnologies

Drug developers are under increasing pressure to reduce the cost and time of bringing new medicines to market amidst growing complexities in drug modalities. Automation and digitalization, proven catalysts in sectors like automotive and advanced manufacturing, offer solutions.

Most pharma companies are actively engaged in digital transformation to improve efficiency, productivity, and quality, while lowering costs across drug discovery, development, and manufacturing. Digital tools are enabling process streamlining, error reduction, and real-time data analytics throughout development and production. Automated systems allow for quicker decisions, ensure consistency, and support more agile production, leading to faster time-to-market without compromising safety or compliance.

FUJIFILM Diosynth Biotechnologies is leading the charge with its innovative kojoX™ modular platform. This integration of cutting-edge digitalization, coupled with a strong commitment to data security, is enabling FUJIFILM Diosynth Biotechnologies to expedite drug development, lower expenses, and guarantee uniform quality throughout its worldwide facilities. With its emphasis on innovation, transparency, and security, FUJIFILM Diosynth Biotechnologies is shaping its operations to meet the evolving demands of the biopharmaceutical sector, establishing new benchmarks for efficiency, reliability, and regulatory adherence.